RxDoctor Payments Data

Aimee Edell, MD

Ophthalmology · San Ramon, CANPI 1740508506

Payments from drug & device makers

$33,773in general payments, 2019–2025

Across 265 payments — averaging $127.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$26K
  • Tarsus Pharmaceuticals, Inc.$2K
  • AbbVie$1K
  • Biotissue Holdings Inc.$571
  • Alcon$396
  • Mallinckrodt Hospital Products Inc.$360
  • plus $3K from 20 others
$5,042in research payments, 2019–2025

Across 3 payments — averaging $1680.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sun Pharmaceutical Industries Inc.$5K

What the payments were for

  • Consulting fees$1,87523%
  • Food & beverage$6,09276%
  • Education$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$33,773 in reported general payments places this provider in the 85th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$276,271
Medicare patients
490
Services billed
1,991

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XdemvyLotilaner27$50,446
CequaCyclosporine30$37,234
RestasisCyclosporine25$28,590
MieboPerfluorohexyloctane/Pf25$22,690
VevyeCyclosporine15$10,841
LumiganBimatoprost16$9,683
ProlensaBromfenac Sodium20$6,864
Prednisolone Acetate87$4,281
Brimonidine Tartrate15$1,459
ValacyclovirValacyclovir Hcl20$1,375
Latanoprost95$1,146
Doxycycline Monohydrate36$885
Fluorometholone11$789
Azithromycin24$122

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Tarsus Pharmaceuticals, Inc.Xdemvy$2,396$50,44627 claims
AbbVieRestasis, Lumigan$1,224$38,27241 claims
Sun Pharmaceutical Industries Inc.Cequa$26,296$37,23430 claims
Bausch & Lomb Americas Inc.Miebo$330$22,69025 claims
Harrow Eye, LLCVevye$196$10,84115 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$331$6,86420 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in San Ramon

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →